Biopsy

GENFIT to Present Update on Scientific and Corporate Progress at The Liver Meeting® 2023

Retrieved on: 
Thursday, November 2, 2023
Transplant, Labcorp, UCSF, American Association for the Study of Liver Diseases, BMI, Hepatology, MD, University of California, MBA, ACLF, PBC, Gubra, NAS, Poster, Division, NASH, GAN, Biopsy, University, CET, Primary biliary cholangitis, FACP, Ipsen, Patient, Abstract, Liver support system, IQVIA, AASLD, Medical device, Pharmaceutical industry, Medical imaging, Euronext, Gastroenterology

Participants include study investigators, principal investigators and other healthcare professionals from the US, France, Germany and the UK.

Key Points: 
  • Participants include study investigators, principal investigators and other healthcare professionals from the US, France, Germany and the UK.
  • Two Patient Advocacy Council sessions will be held on Saturday November 11, 2023.
  • Participants in this event include Dr. Jennifer Lai (MD, MBA, FACP) and the Global Liver Institute.
  • GENFIT will present new data on its NASH diagnostics technology, including:
    The impact of BMI on NIS2+™ and established non-invasive tests for the evaluation of non-alcoholic liver disease (15’ Oral Presentation #238, Pr.

ARTIDIS Launches Groundbreaking ANGEL Study With Over 2,700 Participants: Transforming Breast Cancer Diagnosis and Personalized Therapy Optimization at the Patient's Bedside

Retrieved on: 
Thursday, November 2, 2023
Trial of the century, MRI, NAT, Literature, Liver, Baylor University, Breast Cancer Awareness Month, University Hospital of Basel, Nanomechanics, Malignancy, Neoadjuvant therapy, Baylor College of Medicine, Mammography, Aggression, NANO, Breast cancer, Biopsy, Travel, Skin, Patient, Diagnosis, Medical imaging

The study aims to enroll over 2,700 patients, generating comprehensive insights into all breast cancer subtypes.

Key Points: 
  • The study aims to enroll over 2,700 patients, generating comprehensive insights into all breast cancer subtypes.
  • Dr. Alastair Thompson commented, “As a breast surgeon, I believe this study holds immense importance for breast cancer patients.
  • The ANGEL study specifically addresses the key challenges of personalized diagnosis and treatment decision-making, particularly in the field of neoadjuvant therapy.
  • Ensuring patients receive the best possible treatment from the start is crucial for improving outcomes for breast cancer patients.

Scholar Rock Presents New Data from Phase 1 DRAGON Trial Showing Promising Anti-Tumor Activity in Anti-PD-1 Resistant Metastatic ccRCC Patients and Supporting SRK-181 Continued Tolerability

Retrieved on: 
Friday, November 3, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Society for Immunotherapy of Cancer, Neoplasm, Patient, FRCP, MDSC, PRS, NSCLC, Poster, PD, Aes, UC, Publication, Vomiting, DCR, Diarrhea, Pembrolizumab, Metastasis, Associate professor, Safety, Conference, Doctor of Philosophy, MBBS, Data, Nausea, CD8, Rash, Cancer immunotherapy, Immunotherapy, Rock, SD, DRAGON, SITC, San Diego Convention Center, Biopsy, Annual general meeting, ORR, University, RECIST, Biomarker, Melanoma, Lung cancer, Society, Therapy, AE, Carcinoma, Spectrochimica Acta Part B, Dermatitis, PR, Toxic epidermal necrolysis, Pharmaceutical industry, Medical imaging, Nightclub, Part

The second poster focuses on preliminary biomarker data from part B of the trial in patients with multiple tumor types.

Key Points: 
  • The second poster focuses on preliminary biomarker data from part B of the trial in patients with multiple tumor types.
  • Data presented continues to support proof of concept for SRK-181 in 28 heavily pretreated patients with ccRCC resistant to anti-PD-1.
  • In the biomarker analysis for ccRCC, levels of circulating granulocytic myeloid-derived suppressor cells (gMDSC) correlated with clinical activity in ccRCC patients treated with SRK-181 in combination with pembrolizumab.
  • “The DRAGON trial has successfully delivered on its objective of demonstrating proof of concept for SRK-181 by showing promising anti-tumor activity.

Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting

Retrieved on: 
Friday, November 3, 2023
Technology, Genetics, Health Technology, Software, Biotechnology, Health, Pharmaceutical, General Health, Oncology, SNV, Taxane, Plasma, Stomach, Paclitaxel, Bladder cancer, Research, Cancer, Poster, HNSCC, Pharmacokinetics, SITC, Immunotherapy, Drug discovery, Biopsy, Annual general meeting, Head and neck cancer, RECIST, Biliary tract, Society, Therapy, Liquid biopsy, Patient, Neoplasm, Prostate, PR, Pharmaceutical industry, Medical imaging, Illumina

Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced data from two poster presentations being presented tomorrow, November 4, 2023, at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA.

Key Points: 
  • Fulgent Genetics, Inc. (NASDAQ: FLGT) (“Fulgent” or the “Company”), a technology-based company with a well-established clinical diagnostic business and a therapeutic development business, today announced data from two poster presentations being presented tomorrow, November 4, 2023, at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting in San Diego, CA.
  • The study calls for the involvement of certified labs, highlighting the need for stringent quality management and regulatory alignment.
  • The poster titled, “FID-007: Nanoencapsulated Paclitaxel Derived from a Novel Nano-Drug Delivery Platform,” highlights progress for Fulgent Pharma’s lead therapeutic oncology candidate, FID-007, in various cancers.
  • Preliminary clinical data suggests FID-007 may have anti-tumor activity in heavily pre-treated patients across various tumor types.

Natera’s Landmark RenaCARE Study Demonstrates Significant Diagnostic and Clinical Utility of Renasight™ in Chronic Kidney Disease

Retrieved on: 
Thursday, November 2, 2023
Biotechnology, Medical Devices, Health, Genetics, Oncology, Genetic testing, Patient, Journal of the American Society of Nephrology, Kidney disease, Columbia University Irving Medical Center, Hematuria, Therapy, Medicare, Physician, AUC, Diabetes, NTRA, Journal, Society, Chronic kidney disease, Disease, Division, Medicine, Hypertension, Histology, Biopsy, Nephrology, CKD, Diagnosis, DNA, Pharmaceutical industry, Medical imaging, Dietary supplement

Genetic testing can address many of these limitations by identifying the underlying origin of disease, enabling physicians to properly diagnose and stratify CKD patients.

Key Points: 
  • Genetic testing can address many of these limitations by identifying the underlying origin of disease, enabling physicians to properly diagnose and stratify CKD patients.
  • In the RenaCARE study, 20.8% of CKD patients had a positive genetic finding.
  • Of those, 48.8% of patients received a new or reclassified diagnosis and 34% received information on disease subtype.
  • In the study, 35.5% of patients with positive results received a diagnosis that could make them eligible for available therapeutics.

LUNGevity Foundation's No One Missed Campaign Commemorates Third Year of #KnowYourBiomarker Storytelling Initiative

Retrieved on: 
Wednesday, November 1, 2023
Aurora, Insurance, NSCLC, Cancer Support Community, Lung cancer, Wellstar Health System, Organization, Hope, Northside Hospital, ALK, Research, Progress, Chest pain, Disease, Winship Cancer Institute, NED, Radiation, Emory University, Biopsy, CT, X-ray, Immunotherapy, Personalized medicine, Fertility preservation, Cancer, Patient, Diagnosis, Prognosis, Mutation, EGFR, Medical imaging, Atlanta

WASHINGTON, Nov. 1, 2023 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit, today celebrates the third year of #KnowYourBiomarker, a social media initiative that highlights the stories of people living well with lung cancer. The initiative is part of LUNGevity's No One Missed campaign aimed at driving awareness of comprehensive biomarker testing in non-small cell lung cancer (NSCLC).

Key Points: 
  • She started chemotherapy, which resulted in awful side effects that prevented her from being able to work.
  • After her healthcare team ordered biomarker testing, they discovered her cancer was positive for the ALK mutation and matched Shirley with a targeted therapy.
  • Now, three years after her diagnosis, Shirley is living her life to the fullest.
  • In addition to No One Missed's #KnowYourBiomarker initiative, LUNGevity has other ways to get involved during Lung Cancer Awareness Month.

Dr. Maximilian Diehn Receives LUNGevity's 2023 Lung Cancer Early Detection Award

Retrieved on: 
Wednesday, November 1, 2023
Gold, MPH, Lung cancer, Doctor of Philosophy, Lung cancer screening, Research, Quality of life, Methylation, Disease, Partnership, Biopsy, CT, Blood, Cancer, Patient, Diagnosis, Prognosis, DNA, Uranium mining, Medical imaging, MD

WASHINGTON, Nov. 1, 2023 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is proud to announce Maximilian Diehn, MD, PhD, as the recipient of LUNGevity's 2023 Lung Cancer Early Detection Award. Dr. Diehn's work builds on LUNGevity's 15-year focus on funding research into the early detection of lung cancer and continues its investment in developing a noninvasive blood test to detect lung cancer in its earliest stages. 

Key Points: 
  • WASHINGTON, Nov. 1, 2023 /PRNewswire/ -- LUNGevity Foundation, the nation's leading lung cancer-focused nonprofit organization, is proud to announce Maximilian Diehn, MD, PhD, as the recipient of LUNGevity's 2023 Lung Cancer Early Detection Award.
  • The 2023 Lung Cancer Early Detection Award recipient is:
    Dr. Diehn and his team have already developed three different blood tests for the early detection of lung cancer.
  • "This award program supports research to help us reimagine the early detection of lung cancer and make it easier for doctors to find lung cancer in earlier stages," said Dr. Basu Roy.
  • LUNGevity's 2023 Lung Cancer Early Detection Award is funded in partnership with Carla and Alan Braverman.

Body Vision Medical Awarded Agreement with Premier, Inc.

Retrieved on: 
Tuesday, October 31, 2023
Survival, Premier, Lung cancer, Patient Centered Primary Care Collaborative, Premier, Inc., Health, Artificial intelligence, Hospital, Biopsy, CT, Patient, Diagnosis, Nursing, Medical imaging

CAMPBELL, Calif., Oct. 31, 2023 /PRNewswire/ -- Body Vision Medical, a leader in AI-driven, intraoperative imaging, announced today it was awarded a national "Mobile C-Arms" purchasing agreement with Premier, Inc. for the LungVision system.

Key Points: 
  • CAMPBELL, Calif., Oct. 31, 2023 /PRNewswire/ -- Body Vision Medical, a leader in AI-driven, intraoperative imaging, announced today it was awarded a national "Mobile C-Arms" purchasing agreement with Premier, Inc. for the LungVision system.
  • Effective December 1, 2023, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for Body Vision's LungVision™ AI-powered image-guidance platform for lung nodule biopsy.
  • "This marks an extraordinary opportunity to expand access to LungVision™ real-time intraoperative imaging to Premier's members for the betterment of their patients."
  • Body Vision Medical's LungVision™ system uses artificial intelligence (AI) to transform X-ray images from any C-arm into real-time, intraoperative CT scans.

Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)

Retrieved on: 
Sunday, October 22, 2023
Abdominal pain, FDA, Adolescence, Headache, American College, Ageing, Icahn School of Medicine at Mount Sinai, Aes, Food, Injection site reaction, ACG, Priority, American College of Gastroenterology, Regeneron Pharmaceuticals, Inflammation, Eating, Priority review, Cough, PESQ, COVID-19, Mount Sinai, Eosinophilic esophagitis, Biopsy, Safety, Patient, Food and Drug Administration, Failure, Pharmaceutical industry, Vaccine, MPH, Medicine, Part, Sanofi, Dupilumab

PARIS and TARRYTOWN, N.Y., Oct. 22, 2023 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced that positive results from a Phase 3 trial evaluating the investigational use of Dupixent® (dupilumab) showed consistent efficacy and safety for up to one year (52 weeks) in children aged 1 to 11 years with eosinophilic esophagitis (EoE). These results represent the first analysis of longer-term data in this age group and will be featured in a late-breaking session on October 25 at the American College of Gastroenterology (ACG) 2023 Annual Scientific Meeting.

Key Points: 
  • “Dupilumab is the first and only therapeutic approved for adults and certain adolescents with EoE.
  • Some children with EoE may have sub-optimal response to currently unapproved standard of care therapies, underscoring the need for treatments targeting key pathways driving inflammation in EoE.
  • All children in Part B were treated with higher or lower dose Dupixent for an additional 36 weeks, providing up to 52 weeks of data.
  • In Part B, there were 37 patients who continued on higher dose Dupixent and 18 who switched from placebo to higher dose Dupixent.

Press Release: Dupixent® (dupilumab) Phase 3 Results show sustained efficacy for up to one year in children 1 to 11 years of age with eosinophilic esophagitis (EoE)

Retrieved on: 
Sunday, October 22, 2023
Icahn School of Medicine at Mount Sinai, Abdominal pain, FDA, Adolescence, Headache, American College, Ageing, Aes, Food, Injection site reaction, ACG, Priority, American College of Gastroenterology, Inflammation, Eating, Priority review, Cough, PESQ, COVID-19, Eosinophilic esophagitis, Biopsy, Safety, Patient, Food and Drug Administration, Failure, Pharmaceutical industry, Vaccine, Part, Dupilumab

Positive results from a Phase 3 trial demonstrated the efficacy and safety profile of Dupixent® (dupilumab) for up to one year (52 weeks) in children aged 1 to 11 years with eosinophilic esophagitis (EoE) was consistent.

Key Points: 
  • Positive results from a Phase 3 trial demonstrated the efficacy and safety profile of Dupixent® (dupilumab) for up to one year (52 weeks) in children aged 1 to 11 years with eosinophilic esophagitis (EoE) was consistent.
  • Dupilumab is the first and only therapeutic approved for adults and adolescents 12 years and older who weigh at least 40 kg with EoE.
  • All children in Part B were treated with higher or lower dose Dupixent for an additional 36 weeks, providing up to 52 weeks of data.
  • In Part B, there were 37 patients who continued on higher dose Dupixent and 18 who switched from placebo to higher dose Dupixent.